Use of Patient Buddy Application to Disseminate Knowledge & Prevent Readmission

使用患者伙伴应用程序传播知识

基本信息

  • 批准号:
    8904132
  • 负责人:
  • 金额:
    $ 15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-04-06 至 2017-03-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Cirrhosis affects more than 5 million Americans, of whom a substantial percentage requires frequent hospitalization. Several federally studies have demonstrated an unacceptably high rate of preventable readmission in cirrhotics due to consistently identified risk factors. These readmissions are a tremendous burden on patients, caregivers and society. However, the dissemination of measures to prevent readmission in practice using interfaces that improve patient-caregiver and clinician interaction through mobile health technology is limited. Patient Buddy(tm) is a HIPAA-compliant innovative smartphone application developed by our technology partner CITI. This App has separate patient and caregiver interfaces focused on several aspects that impacting readmissions while promoting communication and education. Given this immense gap in knowledge in the prevention of re-hospitalization, our central hypothesis is: Patient Buddy, a mobile patient-caregiver-clinician interface, will effectively reduce readmissions in decompensated cirrhotic patients within 30 days of discharge. We propose to test this using the following two specific aims: Specific aim 1: To perform a pilot and feasibility study of disseminating current knowledge of readmission prevention in cirrhosis by using the Patient Buddy App with patient and caregiver interfaces. Eighty subjects (40 cirrhotic inpatients and 40 caregivers) will be enrolled and trained on the Patient Buddy at discharge. The App focuses on daily communication between patient/caregivers and the study team based on previously identified risk factors associated with readmission. The study team will initiate measures to prevent readmission using these communications. A detailed analysis of 30-day readmissions and input of the patients, caregivers and nurse manager will be performed to improve the App. Specific aim 2: To incorporate the opinion of key stakeholders (patients, caregivers and case managers) towards improving the Patient Buddy App in the prevention of readmission in cirrhosis. The input of the key stakeholders and the analysis of readmissions prevented during the pilot study will be used to update the App for preventing readmissions in future studies This research will improve health quality by accelerating implementation of patient- centered outcomes research on prevention of readmissions, which will make health care safer and more affordable and efficient by preventing unnecessary re-hospitalizations in cirrhosis through an innovative mobile health Application, Patient Buddy.
 描述(由申请人提供):肝硬化影响超过500万美国人,其中相当大的比例需要经常住院治疗。几项联邦研究表明,由于一致确定的风险因素,可预防的再入院率高得令人无法接受。这些再入院对患者、护理人员和社会都是巨大的负担。然而,传播的措施,以防止在实践中使用的接口,通过移动的健康技术,改善病人-护理人员和临床医生的互动再入院是有限的。Patient Buddy(tm)是由我们的技术合作伙伴CITI开发的符合HIPAA标准的创新智能手机应用程序。该应用程序具有单独的患者和护理人员界面,重点关注影响再入院的几个方面,同时促进沟通和教育。鉴于在预防再住院方面的知识存在巨大差距,我们的中心假设是:患者伙伴,一个移动的患者-护理人员-临床医生界面,将有效减少失代偿性心脏病患者在出院后30天内的再入院率。我们建议使用以下两个具体目标来测试这一点:具体目标1:通过使用具有患者和护理人员界面的患者好友应用程序,对传播肝硬化再入院预防的当前知识进行试点和可行性研究。将入组80名受试者(40名中风住院患者和40名护理人员),并在出院时接受患者伙伴培训。该应用程序侧重于患者/护理人员与研究团队之间的日常沟通,基于先前确定的与再入院相关的风险因素。研究小组将使用这些通信采取措施防止再入院。将对30天再入院和患者、护理人员和护士管理人员的意见进行详细分析,以改进应用程序。具体目标2:纳入关键利益相关者(患者、护理人员和病例管理人员)的意见,以改进Patient Buddy应用程序,预防肝硬化再入院。关键利益相关者的输入和在试点研究期间预防的再入院分析将用于更新应用程序,以防止未来研究中的再入院。这项研究将通过加速实施以患者为中心的预防再入院的结果研究来改善健康质量,这将使医疗保健更安全,更负担得起,更有效地防止不必要的重新-通过创新的移动的健康应用程序Patient Buddy,帮助肝硬化患者住院治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jasmohan S Bajaj其他文献

WED-383 - Serum ammonia levels do not correlate with overt hepatic encephalopathy severity and time to resolution in hospitalized patients with cirrhosis
  • DOI:
    10.1016/s0168-8278(23)00853-x
  • 发表时间:
    2023-06-01
  • 期刊:
  • 影响因子:
  • 作者:
    Jasmohan S Bajaj;Nikolaos T. Pyrsopoulos;Robert Rahimi;Zeev Heimanson;Christopher Allen;Robert Israel;Don Rockey
  • 通讯作者:
    Don Rockey
THU023 - Active alcohol misuse is linked with lower short-chain fatty acid producing microbiota in a matched study of 450 patients with cirrhosis
THU023 - 在一项针对 450 例肝硬化患者的配对研究中,积极的酒精滥用与短链脂肪酸产生微生物群减少有关
  • DOI:
    10.1016/s0168-8278(22)00643-2
  • 发表时间:
    2022-07-01
  • 期刊:
  • 影响因子:
    33.000
  • 作者:
    Jasmohan S Bajaj;Amirhossein Shamsaddini;Masoumeh Sikaroodi;Brian Davis;Puneet Puri;Michael Fuchs;Andrew Fagan;Sara McGeorge;Patrick Gillevet
  • 通讯作者:
    Patrick Gillevet
THU494 - Serum metabolites on admission associate with the development of nosocomial infections in inpatients with cirrhosis
THU494 - 入院时的血清代谢物与肝硬化住院患者医院感染的发生发展相关
  • DOI:
    10.1016/s0168-8278(22)01041-8
  • 发表时间:
    2022-07-01
  • 期刊:
  • 影响因子:
    33.000
  • 作者:
    Jasmohan S Bajaj;Jacqueline O’Leary;Puneeta Tandon;Guadalupe Garcia-Tsao;Patrick S. Kamath;Paul J. Thuluvath;Ram Subramanian;Hugo E. Vargas;Sara McGeorge;Andrew Fagan;Florence Wong;Jennifer Lai;Leroy Thacker;Rajender Reddy
  • 通讯作者:
    Rajender Reddy
FRI-546 - Nosocomial infections in cirrhosis are unpredictable and vary based on region of the world: CLEARED study
  • DOI:
    10.1016/s0168-8278(23)00733-x
  • 发表时间:
    2023-06-01
  • 期刊:
  • 影响因子:
  • 作者:
    Jasmohan S Bajaj;Florence Wong;Qing Xie;Patrick S. Kamath;Mark Topazian;Shiv Kumar Sarin;Shiva Kumar;Sebastián Marciano;Fiona Tudehope;Robert Gibson;Adam Doyle;Stephen Riordan;Alberto Queiroz Farias;Nabiha Faisal;Puneeta Tandon;Marie Jeanne Lohoues;Carlos Benitez;Yongchao Xian;Chuanwu Zhu;Minghua Su
  • 通讯作者:
    Minghua Su
SAT496 - SBP vs. non-SBP bacterial infections at admission have comparable outcomes in a multi-center cohort of inpatients with cirrhosis
在一项多中心肝硬化住院患者队列中,入院时 SAT496 - SBP 与非 SBP 细菌感染的结局相当
  • DOI:
    10.1016/s0168-8278(22)02066-9
  • 发表时间:
    2022-07-01
  • 期刊:
  • 影响因子:
    33.000
  • 作者:
    Jacqueline O’Leary;K.Rajende Reddy;Puneeta Tandon;Patrick S. Kamath;Guadalupe Garcia-Tsao;Flornce Wong;Jennifer C Lai;Ram Subramanian;Paul J. Thuluvath;Benedict Maliakkal;Hugo E. Vargas;Scott Biggins;Leroy Thacker;Jasmohan S Bajaj
  • 通讯作者:
    Jasmohan S Bajaj

Jasmohan S Bajaj的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jasmohan S Bajaj', 18)}}的其他基金

Fecal microbiota transplant for Alcohol-Associated Cirrhosis
粪便微生物群移植治疗酒精相关性肝硬化
  • 批准号:
    10703378
  • 财政年份:
    2022
  • 资助金额:
    $ 15万
  • 项目类别:
Fecal microbiota transplant for Alcohol-Associated Cirrhosis
粪便微生物群移植治疗酒精相关性肝硬化
  • 批准号:
    10444624
  • 财政年份:
    2022
  • 资助金额:
    $ 15万
  • 项目类别:
BCCMA: Targeting Gut Microbiome in Gastrointestinal and Liver Diseases in US Veterans; CMA4: At the Crossroads of the Gut Microbiome, Cirrhosis, and PTSD
BCCMA:针对美国退伍军人胃肠道和肝脏疾病中的肠道微生物组;
  • 批准号:
    10475994
  • 财政年份:
    2022
  • 资助金额:
    $ 15万
  • 项目类别:
Liver Cirrhosis Network: Clinical Research Centers
肝硬化网络:临床研究中心
  • 批准号:
    10487561
  • 财政年份:
    2021
  • 资助金额:
    $ 15万
  • 项目类别:
Liver Cirrhosis Network: Clinical Research Centers
肝硬化网络:临床研究中心
  • 批准号:
    10700058
  • 财政年份:
    2021
  • 资助金额:
    $ 15万
  • 项目类别:
Liver Cirrhosis Network: Clinical Research Centers
肝硬化网络:临床研究中心
  • 批准号:
    10308126
  • 财政年份:
    2021
  • 资助金额:
    $ 15万
  • 项目类别:
Gut Microbiota in the Modulation of Outcomes after Liver Transplant
肠道微生物群对肝移植后结果的调节
  • 批准号:
    10231248
  • 财政年份:
    2020
  • 资助金额:
    $ 15万
  • 项目类别:
Gut Microbiota in the Modulation of Outcomes after Liver Transplant
肠道微生物群对肝移植后结果的调节
  • 批准号:
    10054215
  • 财政年份:
    2020
  • 资助金额:
    $ 15万
  • 项目类别:
Health IT generated PROs to Improve Outcomes in Cirrhosis
健康 IT 生成 PRO 来改善肝硬化的治疗结果
  • 批准号:
    10374779
  • 财政年份:
    2018
  • 资助金额:
    $ 15万
  • 项目类别:
Modulation of Gut-Brain Axis Using Fecal Microbiome Transplant Capsules in Cirrhosis
使用粪便微生物移植胶囊调节肝硬化的肠脑轴
  • 批准号:
    9335590
  • 财政年份:
    2017
  • 资助金额:
    $ 15万
  • 项目类别:

相似海外基金

Patient Lifestyle and Disease Data Interactium (PaLaDIn)
患者生活方式和疾病数据交互 (PaLaDIn)
  • 批准号:
    10103989
  • 财政年份:
    2024
  • 资助金额:
    $ 15万
  • 项目类别:
    EU-Funded
Patient Lifestyle and Disease Data Interactium (PaLaDIn)
患者生活方式和疾病数据交互 (PaLaDIn)
  • 批准号:
    10105921
  • 财政年份:
    2024
  • 资助金额:
    $ 15万
  • 项目类别:
    EU-Funded
患者・市民にとってのPPI(Patient and Public Involvement)の有用性の検討
检查 PPI(患者和公众参与)对患者和公民的有用性
  • 批准号:
    24K13672
  • 财政年份:
    2024
  • 资助金额:
    $ 15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Reducing Harm In Ventilated Patients: First In-patient Evaluation Of A Smart Endotracheal Tube
减少通气患者的伤害:智能气管插管的首次住院评估
  • 批准号:
    MR/Y008642/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15万
  • 项目类别:
    Research Grant
Cultivating Diversity Awareness in Japanese Med Schools with a foreign Standardized Patient program
通过外国标准化患者计划培养日本医学院的多样性意识
  • 批准号:
    24K13361
  • 财政年份:
    2024
  • 资助金额:
    $ 15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Patient iPSC-derived brain organoids as a model for cognitive phenotypes of Duchenne muscular dystrophy
患者 iPSC 衍生的脑类器官作为杜氏肌营养不良症认知表型的模型
  • 批准号:
    24K18635
  • 财政年份:
    2024
  • 资助金额:
    $ 15万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
TWINNING: Scalable technologies for creating virtual patient twin populations to accelerate in-silico enabled medical device innovation.
双胞胎:用于创建虚拟患者双胞胎群体的可扩展技术,以加速计算机模拟医疗设备创新。
  • 批准号:
    10103504
  • 财政年份:
    2024
  • 资助金额:
    $ 15万
  • 项目类别:
    Collaborative R&D
MRI-based, patient-specific 3D bone imaging for orthopaedic surgery planning
基于 MRI 的患者特异性 3D 骨成像,用于骨科手术规划
  • 批准号:
    10106117
  • 财政年份:
    2024
  • 资助金额:
    $ 15万
  • 项目类别:
    Launchpad
看護管理情報とPatient/Nurse Outcomeに関するエビデンス創出のためのPlatform開発
开发平台,用于创建有关护理管理信息和患者/护士结果的证据
  • 批准号:
    23K27871
  • 财政年份:
    2024
  • 资助金额:
    $ 15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
TAVI生体弁におけるProsthesis-patient mismatchの適切な評価方法の確立
建立 TAVI 生物瓣膜假体与患者不匹配的适当评估方法
  • 批准号:
    24K11278
  • 财政年份:
    2024
  • 资助金额:
    $ 15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了